Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).
Anuja NeveBibha DasJakub WojtowiczZhiyue HuangSzofia BullainMichelle WatkinDominik LottTobias BittnerPaul DelmarGregory KleinCarsten HofmannGeoffrey A KerchnerJanice SmithMonika BaudlerPaulo FontouraRachelle S DoodyPublished in: Journal of Alzheimer's disease : JAD (2024)
SC gantenerumab at doses of up to 1,200 mg Q4W were well tolerated in participants with mild AD dementia.